Tofacitinib in Recurrent GBM Patients
| 适应症 | Glioblastoma |
|---|---|
| 分期 | 3期 |
| 申办方 | University of Texas Southwestern Medical Center |
| 状态 | 已完成 |
| 受试者人数 | 18 人 |
| 干预（药物） | Tofacitinib 10mg, Temozolomide, Lomustine |
| 开始日期 | 2022年10月7日 |
| 完成日期 | 2025年2月18日 |
| 结果公布日 | 2026年6月29日 |
摘要
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.
| Newly Diagnosed or Recurrent Off Temozolomide | 4 months |
|---|---|
| Recurrent Disease on Temozolomide | 4 months |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen